Loading
Prevention drug trials run separately in each precancer and are slow. One master protocol with shared infrastructure across Barrett's oesophagus, oral leukoplakia, lung nodules and pancreatic cysts, using regression as an intermediate endpoint and adding or dropping arms adaptively, would test several drugs at once.
Each precursor cohort has small stand-alone chemoprevention trials. Propose a master protocol with shared infrastructure, biomarker-defined precursor cohorts, intermediate endpoints (regression, progression-free interval), and adaptive arm addition and dropping, funded jointly by NCI's prevention network and philanthropy.
One bottleneck page and 27 idea pages on OnCo cite this paper by its DOI; this record gives the citation a page of its own so a reader can follow it without leaving OnCo. Read the abstract above alongside the citing pages listed under Related; the record was created automatically from the Europe PMC entry and its figures have not been checked by hand.
For women at raised risk, a 5-year course of tamoxifen offers long-lasting protection against the commonest kind of breast cancer. Uptake is low because of side effects and fear of rare serious harms; low-dose tamoxifen (TAM-01) is now being tested to improve the balance. It has not been shown to save lives.
A Mediterranean dietary pattern rich in olive oil may lower breast cancer risk, and it is safe and good for the heart anyway. The evidence is suggestive, not definitive, because of the small number of cancers; it should not be presented as proven cancer prevention.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares IBIS-I: five years of tamoxifen keeps preventing breast cancer for at least 20 years, Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers, Prevention we already have is not deployed.
Shares Proportion and number of cancer cases and deaths attributable to potentially modifiable risk factors in the United States, Chemoprevention & risk-reducing surgery, Prevention we already have is not deployed.